TCL Archive Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer February 25, 2011
TCL Archive Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study November 26, 2010
TCL Archive National Cancer Survey Data Available Soon: NCI Will Invite Investigators to Prepare Analysis August 23, 1974
TCL Archive BCDDP Follow Up To Cost $1.6 Million annually For Five Years Okayed; Limited To 59,000 Women November 3, 1978
